PRE trades 65.1% below Wall Street's consensus target of $37.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes PRE achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 2 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Prenetics Global Limited (PRE) has a Wall Street consensus price target of $37.50, based on estimates from 2 covering analysts. With the stock currently trading at $22.71, this represents a potential upside of +65.1%. The company has a market capitalization of $386M.
Analyst price targets range from a low of $35.00 to a high of $40.00, representing a 13% spread in expectations. The median target of $37.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, PRE trades at a trailing P/E of -8.5x. Analysts expect EPS to grow +11.6% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 EXASExact Sciences Corporation | $20.0B | $104.91 | $92.95 | -11.4% | Buy | 582.8x | 41 |
 NTRANatera, Inc. | $56.0B | $390.79 | $335.07 | -14.3% | Buy | — | 28 |
 CSTLCastle Biosciences, Inc. | $1.1B | $34.88 | $39.00 | +11.8% | Buy | — | 11 |
 QDELQuidelOrtho Corporation | $705M | $10.34 | $12.25 | +18.5% | Hold | 13.4x | 15 |
 AHCOAdaptHealth Corp. | $776M | $5.70 | $9.83 | +72.5% | Buy | — | 12 |
 HIMSHims & Hers Health, Inc. | $6.3B | $28.39 | $32.17 | +13.3% | Hold | — | 20 |
 MYRGMYR Group Inc. | $4.6B | $295.18 | $444.40 | +50.6% | Hold | 24.2x | 21 |
 TMOThermo Fisher Scientific Inc. | $247.2B | $665.30 | $623.36 | -6.3% | Buy | 26.5x | 43 |
 DHRDanaher Corporation | $155.9B | $221.70 | $223.77 | +0.9% | Buy | 26.1x | 43 |
 IQVIQVIA Holdings Inc. | $44.1B | $267.86 | $246.13 | -8.1% | Buy | 20.7x | 45 |
Quick answers to the most common questions about buying PRE stock.
The consensus Wall Street price target for PRE is $37.5, representing 65.1% upside from the current price of $22.71. With 2 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
PRE has a consensus rating of "Buy" based on 2 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $37.5 implies 65.1% upside from current levels.
PRE's current price is $22.71 with a consensus target of $37.5 (65.1% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $40 for PRE, while the most conservative target is $35. The consensus of $37.5 represents the median expectation. These targets typically reflect 12-month expectations.
PRE is lightly followed, with 2 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PRE stock forecast based on 2 Wall Street analysts shows a consensus price target of $37.5, with estimates ranging from $35 (bear case) to $40 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on PRE, with a "Buy" consensus rating and $37.5 price target (65.1% upside). 2 of 2 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PRE analyst price targets range from $35 to $40, a 13% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $37.5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.